Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Viralytics
ClinicalTrials.gov Identifier:
NCT00636558
First received: March 7, 2008
Last updated: June 7, 2012
Last verified: June 2012
  Purpose

Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.


Condition Intervention Phase
Melanoma
Breast Cancer
Prostate Cancer
Drug: CVA21
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak™ (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours

Resource links provided by NLM:


Further study details as provided by Viralytics:

Primary Outcome Measures:
  • The primary objective of the study is to determine the safety and tolerability of CVA21 given by intravenous infusion in multiple escalating doses. [ Time Frame: Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To obtain preliminary efficacy data, determine the time course of viraemia and its elimination post-administration of CVA21 [ Time Frame: Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84 ] [ Designated as safety issue: Yes ]
  • To characterise the time course of the anti-CVA21 antibody response [ Time Frame: Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84 ] [ Designated as safety issue: Yes ]

Enrollment: 8
Study Start Date: March 2008
Study Completion Date: June 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
IV administration of CVA21 in a dose escalation manner
Drug: CVA21
IV infusion, dose escalation of one or two infusions of escalating strength

Detailed Description:

This is a phase I, multiple dose, dose escalation, open label, cohort study of three intravenous doses of Coxsackie virus A21 in patients with stage IV solid tumours. Prospective patients will attend the study centre for initial screening within 28 days prior to commencement of treatment. They will have the nature of the study and its procedures and risks fully explained. Patients must then sign an informed consent form giving permission for tumour testing before initial screening can be commenced.

Patients whose tumours test positive for ICAM-1 with or without DAF will attend the study centre for a further screening visit within 14 days prior to commencement of treatment. They will sign a full study informed consent form before any further screening procedures are carried out.

Patients who satisfy all inclusion and none of the exclusion criteria will commence the treatment stage, which consists of one or more doses of CVA21 administered by intravenous infusion as per the dosage escalation chart. The first 4 cohorts will be treated as in-patients. The follow up period will consist of 12 weeks, during which time patients will attend the trial centre for up to13 follow up visits to collect safety and efficacy data.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who are willing and able to provide written informed consent to participate in the study.
  2. Male or female aged 18 years or older.
  3. Stage IV solid tumour disease with the primary tumour being any one of the following types - breast, prostate or melanoma.
  4. ICAM-1 with or without DAF-expressing tumour. Patients without archival material for testing must agree to a new tumour biopsy.
  5. Absence of circulating antibodies to CVA21 (titre < 1:16).
  6. Patients must have failed or refused standard treatment(s).
  7. Adequate haematological, hepatic and renal function, defined as:

    • ANC > 1.5 x 10^9/L, platelets > 100 x 10^9/L
    • Bilirubin < 20µmol/L, AST < 2.5 times the upper limit of normal
    • Calculated creatinine clearance > 30 mL/minute
  8. Adequate immunologic function, defined as:

    • Serum IgG > 5g/L
    • T cell subsets within normal limits
  9. Fertile males and females must agree to the use of an adequate form of contraception. Hormonal contraceptives should be supplemented with an additional barrier method. Negative pregnancy test is required in female patients of child-bearing potential.

Exclusion Criteria:

  1. Presence or history of Central Nervous System (CNS) malignancy.
  2. Patients must not have received chemotherapy within 4 weeks prior to date of consent.
  3. Performance status > 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
  4. Life expectancy < 6 months.
  5. Pregnancy or breastfeeding.
  6. Primary or secondary immunodeficiency, including immunosuppressive disease, and immunosuppressive doses of corticosteroids (e.g. prednisolone > 7.5mg per day) or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks.
  7. Positive serology for HIV, hepatitis B or hepatitis C.
  8. Splenectomy.
  9. Presence of uncontrolled infection.
  10. Presence of unstable neurological disease.
  11. Any uncontrolled medical condition that in the opinion of the Investigator is likely to place the patient at unacceptable risk during the study or reduce their ability to complete the study
  12. Participation in another study requiring administration of an investigational drug or biological agent within the last 4 weeks
  13. Known allergy to treatment medication or its excipients
  14. Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00636558

Locations
Australia, New South Wales
Cancer Care Centre, St George Hospital
Kogarah, Sydney, New South Wales, Australia, 2217
Australia, Queensland
Redcliffe Hospital
Redcliffe, Queensland, Australia, 4020
Sponsors and Collaborators
Viralytics
Investigators
Principal Investigator: Boris Chern, MD Redcliffe Hospital, Brisbane, Qld., Australia
Principal Investigator: Winston Liauw, MD St George Hospital
  More Information

No publications provided

Responsible Party: Viralytics
ClinicalTrials.gov Identifier: NCT00636558     History of Changes
Other Study ID Numbers: PSX-X04
Study First Received: March 7, 2008
Last Updated: June 7, 2012
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Viralytics:
coxsackie virus
melanoma
breast cancer
prostate cancer

Additional relevant MeSH terms:
Breast Neoplasms
Coxsackievirus Infections
Melanoma
Prostatic Neoplasms
Breast Diseases
Enterovirus Infections
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Picornaviridae Infections
Prostatic Diseases
RNA Virus Infections
Skin Diseases
Urogenital Neoplasms
Virus Diseases

ClinicalTrials.gov processed this record on October 22, 2014